• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sinomed launches HT Supreme drug-eluting stent in Europe

August 17, 2021 By Sean Whooley

SinomedSinomed has completed the first commercial implantation of its HT Supreme drug-eluting stent in Ireland.

Faisal Sharif, professor of translational cardiovascular medicine and innovation at the National University of Ireland Galway, successfully performed the first procedure with HT Supreme, a healing-targeted drug-eluting stent designed to treat patients with narrowing or blockages to their coronary arteries.

“We are delighted to implant the HT Supreme stent from Sinomed at University Hospital Galway in partnership with National University of Ireland Galway,” Sharif said in a news release. “Early indications show the device deliverability to be good and the novel stent technology offers faster stent endothelialization, which will potentially reduce the need for aggressive antiplatelet treatment. Reducing the need for multiple antiplatelet treatment is an important issue especially with an aging population and multiple co-morbidities of patients who require coronary stenting.”

Tianjin, China–based Sinomed said the new device offers clinicians an additional choice of a device tailored to help patients accelerate wound-healing and restore their naturally protective vessel function after a stenting procedure.

Sharif and three other investigators are overseeing the Pioneer IV trial, a prospective, randomized trial enrolling 2,540 patients suffering from any type of coronary artery disease across 30 hospitals in Europe. Patients will undergo a non-invasive physiological vessel selection to determine which vessel requires stenting and all patients enrolled will use the HT Supreme drug-eluting stent to undergo one-month dual-antiplatelet therapy after stenting.

“The HT Supreme represents a different DES technology by offering a solution specifically designed to encourage rapid healing following implantation,” Sinomed chief commercial officer for sales, marketing and clinical affairs Alain Aimonetti said. “This product launch is a significant landmark for Sinomed Europe as we begin the commercial phase of our operations. Additionally, we will continue our clinical commitment with further investments in the HT Supreme’s robust clinical program.”

Filed Under: Business/Financial News, Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stents, Vascular Tagged With: drug-eluting stent, drug-eluting stents, HT Supreme, Sinomed, vv

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS